HealthTech investing is more complex than traditional software. Regulatory approval takes 12-36 months. Reimbursement decisions can make or break a company. Clinical validation requirements raise costs. The investor base is specialized — not every VC understands the regulatory landscape. This means founders need to know how to position themselves for the right investors.
This guide covers the unique dynamics of HealthTech fundraising, which investors specialize in different segments, and what they're looking for.
HealthTech as an Investment Category
HealthTech spans a wide range:
- Digital Therapeutics (DTx): Software that treats or manages medical conditions (regulatory approval required)
- Medical Devices (SaMD): Software as a medical device (CE Mark or FDA clearance required)
- Healthcare IT (HIT): Administrative software (scheduling, billing, EHR). Usually lower regulatory burden
- Telemedicine / Remote Care: Digital patient-doctor interaction platforms
- Biotech-Adjacent: Data analysis, AI for drug discovery (often venture-backed like traditional software)
The regulatory burden varies dramatically. A scheduling app needs much less regulatory work than a device that monitors glucose levels.
HealthTech Investor Types
Tier 1: Specialized HealthTech VCs
Examples: Lively (Switzerland), Kaleida Health Partners, Cherry Ventures (biotech), Ability Partners
- Check size: €500k-€10M
- Focus: Clinical evidence, regulatory pathways, reimbursement strategy
- Expected background: VC partners with healthcare credentials
Tier 2: Generalist VCs with HealthTech Portfolio
Examples: Accel, Sequoia, Eurazeo (with healthcare practice)
- Check size: €2-20M+
- Focus: Large markets, strong team, path to exit
- Expected metrics: Similar to SaaS but with clinical validation considerations
Tier 3: Corporate VCs and Strategic Investors
Examples: Siemens Venture Capital, Philips Innovation, Hospital Networks, Insurance Companies
- Check size: Variable
- Focus: Strategic fit with their portfolio
Critical HealthTech Metrics & Milestones
| Milestone | Seed Stage | Series A Stage | Importance |
|---|---|---|---|
| Regulatory Clearance | CE Mark or similar (minimum) | CE Mark + FDA 510(k) or approval roadmap | Critical. No funding without this. |
| Clinical Validation | Pilot data or published study (if applicable) | Published clinical evidence or RCT underway | Depends on type. DTx requires more. |
| Reimbursement | Reimbursement strategy documented | First payers committed or pathway clear | Critical for B2B2C model. |
| Customer Traction | 5-10 pilot customers or letters of intent | 20+ paying customers or hospital partnerships | Proof of market demand. |
| Data Privacy Compliance | GDPR-compliant architecture | ISO 27001 certification (or roadmap) | Essential. Non-negotiable. |
Positioning Your HealthTech Company
1. Lead with Clinical Evidence or Regulatory Roadmap
Investors care less about TAM initially, more about "Why should I believe this works?" Lead with clinical data, regulatory strategy, and timeline.
2. Show Reimbursement Thinking
Can you bill insurance? Are you pursuing NICE appraisal in the UK? DRG coding in Germany? This determines your revenue model and investability.
3. Demonstrate Deep Healthcare Domain Knowledge
Your founding team should include someone who understands healthcare: a physician, a healthcare economist, or someone who's worked in health policy. This credibility matters.
4. Address Data Privacy Proactively
Healthcare data is regulated (HIPAA in US, GDPR + national laws in Europe). Show you take this seriously.
Common HealthTech Funding Mistakes
- Overestimating TAM: "€100B healthcare market = we'll capture 1%" doesn't work. Be specific about addressable segments.
- Ignoring regulatory burden: Many founders raise seed funding, then discover FDA approval costs €5M and takes 3 years. Plan this early.
- Claiming independence from reimbursement: "We'll charge patients directly" works in rare cases (aesthetic, wellness). Most healthcare needs payer approval.
- Weak healthcare team: If your team is "software engineers with healthcare ambitions," investors will be skeptical.
"The best HealthTech founders I've backed understand that healthcare is about evidence, not velocity. They're willing to spend 18 months on clinical validation because they know that's what creates defensibility and exit value." – HealthTech VC Partner
Frequently Asked Questions: HealthTech Fundraising
Q: Can I raise Series A without regulatory approval?
A: Rarely for device/DTx. For HIT or Telemedicine, sometimes. It depends. If you're building something that needs regulatory approval, you should have CE Mark minimum at Series A.
Q: How do I find HealthTech-focused VCs?
A: Look for VCs with portfolio companies in your segment. Check their thesis. Talk to other HealthTech founders about who they pitched. Europe has fewer HealthTech specialists than the US — many use generalist VCs with healthcare interest.
Q: What if my technology is FDA-cleared but not yet reimbursed?
A: Investors will ask: "What's your reimbursement plan?" Have a clear answer: CPT code application timeline, payer conversations started, alternate revenue model if needed.
Sources & Further Reading
This article is based on a review of leading venture capital and fundraising literature plus curated primary sources from the most relevant industry voices. The complete source matrix includes 14 core books and 50+ online resources.
Books
- The Entrepreneurial Bible to Venture Capital — , McGraw-Hill.
- The Power Law — , Penguin Press.
- The Venture Mindset — , Portfolio.
Online Resources & Industry Reports
- State of HealthTech Venture Funding — Rock Health
- HealthTech Funding DACH — Dealroom
- Digital Health Trends — CB Insights
All cited works are available in English or German. Links are recommendations, not affiliated.
Related Articles & Services
Related Articles
Service Page
Capital Intelligence Plattform →More relevant articles
Next Step: Free Strategy Call
Discover in 30 minutes which capital pathways are realistic for your project.
Book Your Call Now →What you now know — and how to use it
- You know the core concepts and can apply them directly to your situation
- You know which mistakes to avoid — saving you time and capital
- You understand how this building block fits into your overall strategy
Ready for the Next Step?
In 30 min, Daniel Huber shows which capital strategy fits your situation.